admin
President Trump took to social media this week to claim a clear win: Bayer is building a new $2.2 billion pharmaceutical manufacturing campus near Columbus, Ohio, and he says his pharmaceutical tariffs made it happen. If you like jobs, factories, and simple cause-and-effect claims, that sounds great. If you like nuance, you can still cheer the result while asking whether tariffs were the sole reason. Either way, Ohio wins — and that matters.
Trump credits pharmaceutical tariffs for the Bayer Ohio campus — and he’s not shy about it
President Trump boasted that his “strong Pharmaceutical Tariffs” led to hundreds of billions in new pharma investments and helped bring manufacturing back to the U.S. He tied the Bayer announcement to his “Build in America” message and said companies are choosing the U.S. because tariffs make importing drug ingredients and finished medicines more costly. That political message lands well in Ohio, a state that wants good manufacturing jobs and steady paychecks.
Do tariffs really drive onshoring? The short answer is: sometimes
Tariffs change the math. When import costs rise, domestic production looks more attractive. That can push companies to invest at home rather than rely on long supply chains abroad. Critics will wag fingers and call this protectionism; the reality is cruder: businesses follow profit, and policy nudges can redirect investment. Was the Bayer campus only built because of tariffs? Maybe not. But tariffs are a clear policy tool that shifts incentives, and when steel mills or pharma labs open, people in Ohio do not care which policy nudged them — they care about jobs.
MFN, drug prices, and real-world results
The President also links tariffs and MFN moves to lower drug prices for Americans. That claim deserves scrutiny. Tariffs alone can raise costs in some cases, so claiming universal price drops sounds optimistic. But if tariffs are paired with smart trade rules, onshoring, and stronger domestic competition, the long-term result can be lower prices and more stable supplies. The key is follow-through: tax credits, workforce training, and regulatory clarity matter if we want those Bayer jobs to stay and grow.
Here’s the takeaway for conservatives who like results: cheer the onshoring and hold the administration to account for the follow-through. Celebrate the Ohio jobs, but don’t treat a single announcement as the end of a campaign. Keep pushing for policies that make America the best place to build and hire — and let the left keep pretending factories sprout from thin air. This is how you turn headlines into real, local prosperity.
